Literature DB >> 22776973

Pre-surgical treatment with somatostatin analogues in patients with acromegaly: the case for.

D Ferone1, F Gatto, F Minuto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22776973     DOI： 10.1007/BF03345797

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  22 in total

1.  Effect of octreotide pretreatment on surgical outcome in acromegaly.

Authors:  A Colao; D Ferone; P Cappabianca; M L del Basso De Caro; P Marzullo; A Monticelli; A Alfieri; B Merola; A Calì; E de Divitiis; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1997-10       Impact factor: 5.958

2.  Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates.

Authors:  Marco Losa; Pietro Mortini; Laura Urbaz; Paolo Ribotto; Tristana Castrignanó; Massimo Giovanelli
Journal:  J Neurosurg       Date:  2006-06       Impact factor: 5.115

3.  Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study.

Authors:  Ming Shen; Xuefei Shou; Yongfei Wang; Zhaoyun Zhang; Jinsong Wu; Ying Mao; Shiqi Li; Yao Zhao
Journal:  Endocr J       Date:  2010-11-16       Impact factor: 2.349

4.  Presurgical Octreotide: treatment in acromegaly.

Authors:  A Stevenaert; A Beckers
Journal:  Metabolism       Date:  1996-08       Impact factor: 8.694

5.  Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.

Authors:  U Plöckinger; H-J Quabbe
Journal:  Acta Neurochir (Wien)       Date:  2005-04-04       Impact factor: 2.216

6.  Cost-of-illness study in acromegalic patients in Italy.

Authors:  G Didoni; S Grottol; V Gasco; M Battistini; D Ferone; M Giusti; F Ragazzoni; P Ruffo; E Ghigo; F Minuto
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

7.  Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy.

Authors:  Diego Ferone; Wouter W de Herder; Rosario Pivonello; Johan M Kros; Peter M van Koetsveld; Ton de Jong; Francesco Minuto; Annamaria Colao; Steven W J Lamberts; Leo J Hofland
Journal:  J Clin Endocrinol Metab       Date:  2008-01-22       Impact factor: 5.958

Review 8.  Guidelines for acromegaly management: an update.

Authors:  S Melmed; A Colao; A Barkan; M Molitch; A B Grossman; D Kleinberg; D Clemmons; P Chanson; E Laws; J Schlechte; M L Vance; K Ho; A Giustina
Journal:  J Clin Endocrinol Metab       Date:  2009-02-10       Impact factor: 5.958

9.  Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German Acromegaly Register.

Authors:  S Petersenn; M Buchfelder; M Reincke; C M Strasburger; H Franz; R Lohmann; H-J Quabbe; U Plöckinger
Journal:  Eur J Endocrinol       Date:  2008-08-28       Impact factor: 6.664

10.  Efficacy and complications of neurosurgical treatment of acromegaly.

Authors:  Anna Krzentowska-Korek; Filip Gołkowski; Agata Bałdys-Waligórska; Alicja Hubalewska-Dydejczyk
Journal:  Pituitary       Date:  2011-06       Impact factor: 4.107
View more
  4 in total

1.  Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center.

Authors:  Susanna Bacigaluppi; Federico Gatto; Pasquale Anania; Nicola Luigi Bragazzi; Diego Criminelli Rossi; Giulia Benvegnu; Elena Nazzari; Renato Spaziante; Massimo Giusti; Diego Ferone; Gianluigi Zona
Journal:  Endocrine       Date:  2015-05-17       Impact factor: 3.633

2.  Pros and cons in endocrine practice: pre-surgical treatment with somatostatin analogues in acromegaly.

Authors:  Marco Losa; Jens Bollerslev
Journal:  Endocrine       Date:  2016-01-19       Impact factor: 3.633

3.  Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective.

Authors:  Federica Nista; Giuliana Corica; Lara Castelletti; Keyvan Khorrami; Claudia Campana; Francesco Cocchiara; Gabriele Zoppoli; Alessandro Prior; Diego Criminelli Rossi; Gianluigi Zona; Diego Ferone; Federico Gatto
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-07       Impact factor: 5.555

4.  The role of primary pharmacological therapy in acromegaly.

Authors:  Ana Laura Espinosa de los Monteros; Carmen A Carrasco; Alfredo Adolfo Reza Albarrán; Mônica Gadelha; Alin Abreu; Moisés Mercado
Journal:  Pituitary       Date:  2014-01       Impact factor: 4.107
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.